Contributed equally to this work.
The long-term outcome of patients with polycystic liver disease treated with lanreotide
Article first published online: 24 NOV 2011
© 2011 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 35, Issue 2, pages 266–274, January 2012
How to Cite
Chrispijn, M., Nevens, F., Gevers, T. J. G., Vanslembrouck, R., van Oijen, M. G. H., Coudyzer, W., Hoffmann, A. L., Dekker, H. M., de Man, R. A., van Keimpema, L. and Drenth, J. P. H. (2012), The long-term outcome of patients with polycystic liver disease treated with lanreotide. Alimentary Pharmacology & Therapeutics, 35: 266–274. doi: 10.1111/j.1365-2036.2011.04923.x
- Issue published online: 15 DEC 2011
- Article first published online: 24 NOV 2011
- Publication data Submitted 30 August 2011 First decision 9 September 2011 Resubmitted 13 October 2011 Accepted 1 November 2011 EV Pub Online 24 November 2011
Aliment Pharmacol Ther 2012; 35: 266–274
Background Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.
Aim To establish long-term outcome and safety of lanreotide.
Methods This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide.
Results A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR −8% to −1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR −6% to −1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0–6%) 6 months after end of treatment (n = 22).
Conclusions Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.